Catalyst Wire Dossier Catalyst Wire Dossier

Arylia

denosumab · AryoGen Pharmed Co.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Arylia, covering 2020-07-10 to 2020-07-10. Get the full timeline:

Most recent: Clinical Trial Update: Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women [Phase 3]

See pricing